Vitamin K1 and 25(OH)D are independently and synergistically associated with a risk for hip fracture in an elderly population: A case control study

Clinical Nutrition

Volumn 34, Issue 1, 2015, Pages 101-106

  Torbergsen, Anne C ^a,b   Watne, Leiv O ^a,b   Wyller, Torgeir B ^a,b,d   Frihagen, Frede ^a,b   Strømsøe, Knut ^a,b,d   Bøhmer, Thomas ^a,c,d   Mowe, Morten ^a,b,d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Department of General Internal Medicine ^*  (Norway)

^c Nutrition Institutes   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

25(OH)D; BADL; BALP; BMD; Bone markers; CRP; HGS; Hip fracture; IGF 1; K1; OC; Osteocalcin; PTH; RCT; Risk factors; TotOC; UcOC; Vitamin K1

Indexed keywords

25 HYDROXYVITAMIN D; OSTEOCALCIN; PHYTOMENADIONE; 25-HYDROXYVITAMIN D; VITAMIN D;

AGED; ARTICLE; BONE TURNOVER; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GERIATRIC NUTRITION; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL ASSESSMENT; RISK FACTOR; VERY ELDERLY; VITAMIN BLOOD LEVEL; ANALOGS AND DERIVATIVES; BLOOD; BODY MASS; BONE REMODELING; DRUG POTENTIATION; HIP FRACTURES; NORWAY; PHYSIOLOGY; RISK; STATISTICAL MODEL;

AGED; AGED, 80 AND OVER; BODY MASS INDEX; BONE REMODELING; CASE-CONTROL STUDIES; DRUG SYNERGISM; FEMALE; HIP FRACTURES; HUMANS; LOGISTIC MODELS; MALE; NORWAY; ODDS RATIO; OSTEOCALCIN; RISK FACTORS; VITAMIN D; VITAMIN K 1;

EID: 84921436610     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2014.01.016     Document Type: Article

References (32)

1. Lofthus C.M., Osnes E.K., Falch J.A., Kaastad T.S., Kristiansen I.S., Nordsletten L., et al. Epidemiology of hip fractures in Oslo, Norway. Bone 2001, 29:413-418.
2. Gjertsen J.E., Engesaeter L.B., Furnes O., Havelin L.I., Steindal K., Vinje T., et al. The Norwegian Hip Fracture Register: experiences after the first 2 years and 15,576 reported operations. Acta Orthop 2008, 79:583-593.
3. Meyer H.E., Tverdal A., Falch J.A. Risk factors for hip fracture in middle-aged Norwegian women and men. Am J Epidemiol 1993, 137:1203-1211.
4. Meyer H.E., Henriksen C., Falch J.A., Pedersen J.I., Tverdal A. Risk factors for hip fracture in a high incidence area: a case-control study from Oslo, Norway. Osteoporos Int 1995, 5:239-246.
5. Meyer H.E., Tverdal A., Falch J.A. Changes in body weight and incidence of hip fracture among middle aged Norwegians. BMJ 1995, 311:91-92.
6. Kanis J.A., McCloskey E.V., Johansson H., Oden A., Melton L.J., Khaltaev N. Areference standard for the description of osteoporosis. Bone 2008, 42:467-475.
7. Lunt M., Felsenberg D., Adams J., Benevolenskaya L., Cannata J., Dequeker J., et al. Population-based geographic variations in DXA bone density in Europe: the EVOS Study. European Vertebral Osteoporosis. Osteoporos Int 1997, 7:175-189.
8. Burtis C.A., Ashwood Edward R., Bruns David E. Tietz textbook of clinical chemistry and molecular diagnostics 2011, 1733-1793.
9. Seibel M.J. Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 2005, 26:97-122.
10. Hodges S.J., Pilkington M.J., Stamp T.C., Catterall A., Shearer M.J., Bitensky L., et al. Depressed levels of circulating menaquinones in patients with osteoporotic fractures of the spine and femoral neck. Bone 1991, 12:387-389.
11. Seibel M.J., Robins S.P., Bilezikian J.P. Serum undercarboxylated osteocalcin and the risk of hip fracture. JClin Endocrinol Metab 1997, 82:717-718.
12. Seibel M.J. Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis. Clin Biochem Rev 2006, 27:123-138.
13. Szulc P., Chapuy M.C., Meunier P.J., Delmas P.D. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. JClin Invest 1993, 91:1769-1774.
14. Vermeer C., Theuwissen E. Vitamin K, osteoporosis and degenerative diseases of ageing. Menopause Int 2011, 17:19-23.
15. Stevenson M., Lloyd-Jones M., Papaioannou D. Vitamin K to prevent fractures in older women: systematic review and economic evaluation. Health Technol Assess 2009, 13. iii-134.
16. Feskanich D., Weber P., Willett W.C., Rockett H., Booth S.L., Colditz G.A. Vitamin K intake and hip fractures in women: a prospective study. Am J Clin Nutr 1999, 69:74-79.
17. Hart J.P., Shearer M.J., Klenerman L., Catterall A., Reeve J., Sambrook P.N., et al. Electrochemical detection of depressed circulating levels of vitamin K1 in osteoporosis. JClin Endocrinol Metab 1985, 60:1268-1269.
18. Nakano T., Tsugawa N., Kuwabara A., Kamao M., Tanaka K., Okano T. High prevalence of hypovitaminosis D and K in patients with hip fracture. Asia Pac J Clin Nutr 2011, 20:56-61.
19. Kuwabara A., Himeno M., Tsugawa N., Kamao M., Fujii M., Kawai N., et al. Hypovitaminosis D and K are highly prevalent and independent of overall malnutrition in the institutionalized elderly. Asia Pac J Clin Nutr 2010, 19:49-56.
20. Wyller T.B., Watne L.O., Torbergsen A., Engedal K., Frihagen F., Juliebo V., et al. The effect of a pre- and post-operative orthogeriatric service on cognitive function in patients with hip fracture. The protocol of the Oslo Orthogeriatrics Trial. BMC Geriatr 2012, 12:36.
21. Chumlea W.C., Guo S.S., Wholihan K., Cockram D., Kuczmarski R.J., Johnson C.L. Stature prediction equations for elderly non-Hispanic white, non-Hispanic black, and Mexican-American persons developed from NHANES III data. JAm Diet Assoc 1998, 98:137-142.
22. Mahoney F.I., Barthel D.W. Functional evaluation: the barthel index. Md State Med J 1965, 14:61-65.
23. Ozuru R., Sugimoto T., Yamaguchi T., Chihara K. Time-dependent effects of vitamin K2 (menatetrenone) on bone metabolism in postmenopausal women. Endocr J 2002, 49:363-370.
24. Vergnaud P., Garnero P., Meunier P.J., Breart G., Kamihagi K., Delmas P.D. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. JClin Endocrinol Metab 1997, 82:719-724.
25. Sierra J., Villagra A., Paredes R., Cruzat F., Gutierrez S., Javed A., et al. Regulation of the bone-specific osteocalcin gene by p300 requires Runx2/Cbfa1 and the vitamin D3 receptor but not p300 intrinsic histone acetyltransferase activity. Mol Cell Biol 2003, 23:3339-3351.
26. Inoue T., Fujita T., Kishimoto H., Makino T., Nakamura T., Nakamura T., et al. Randomized controlled study on the prevention of osteoporotic fractures (OF study): a phase IV clinical study of 15-mg menatetrenone capsules. JBone Min Metab 2009, 27:66-75.
27. Cranney A., Horsley T., O'Donnell S., Weiler H., Puil L., Ooi D., et al. Effectiveness and safety of vitamin D in relation to bone health. Evid Rep Technol Assess (Full Rep 2007, 1-235.
28. Kanellakis S., Moschonis G., Tenta R., Schaafsma A., van den Heuvel E.G., Papaioannou N., et al. Changes in parameters of bone metabolism in postmenopausal women following a 12-month intervention period using dairy products enriched with calcium, vitamin d, and phylloquinone (Vitamin K(1)) or Menaquinone-7 (Vitamin K (2)): the postmenopausal health study II. Calcif Tissue Int 2012, 90:251-262.
29. Askim M. Vitamin K in the Norwegian diet and osteoporosis. Tidsskr Nor Laegeforen 2001, 121:2614-2616.
30. Apalset E.M., Gjesdal C.G., Eide G.E., Tell G.S. Intake of vitamin K1 and K2 and risk of hip fractures: the Hordaland Health Study. Bone 2011, 49:990-995.
31. Rezaieyazdi Z., Falsoleiman H., Khajehdaluee M., Saghafi M., Mokhtari-Amirmajdi E. Reduced bone density in patients on long-term warfarin. Int J Rheum Dis 2009, 12:130-135.
32. Walsh J.S., Newman C., Eastell R. Heart drugs that affect bone. Trends Endocrinol Metab 2012, 23:163-168.